BGI Offers Partners a Complete Laboratory Solution for the Fight Against COVID-19
BGI is providing its ‘Huo-Yan’ laboratory solution, which allows implementation of rapid detection and diagnosis of patients suspected with COVID-19, as a complete package to partners across the world.
As of March 3, 2020, there are a total of 90,893 reported cases of COVID-19 globally, and 3,110 deaths, according to the WHO. In the past 24 hours, China reported 129 cases, the lowest number of cases for China since the 20th of January. Outside China, 1,848 cases were reported in 48 countries. 12 countries reported cases for the first time, and there are 21 countries with one case currently. (WHO-Coronavirus disease 2019 (COVID-19) Situation Report – 43).
Facing the spread of COVID-19 in a growing number of countries across the world, it is critical that high throughput detection labs are built up in order to increase the efficiency of diagnosis.
BGI has been actively engaged in the fight against the COVID-19. On January 14, BGI successfully developed a Real-Time Fluorescent RT-PCR kit for detecting 2019-nCoV (SARS-CoV-2), which can issue results in 3 hours. The kit was certified by National Medical Products Administration and received CE-IVD marking. The kit is already widely used in China, providing a scientific basis for diagnosis of suspected cases and the discharge of recovered patients.
On February 5 the Huo-Yan Laboratory, an emergency test laboratory run by BGI and designed to handle 10,000 samples daily to detect 2019-nCoV, started trial operation in Wuhan. The Wuhan Laboratory has been promptly followed by newly built or upgraded Huo-Yan labs in Shenzhen, Tianjin, Beijing, and Shanghai, in a total of 12 cities across the country. The daily throughput totals up to 50,000 tests per day, further upgradable to 80,000 per day when necessary.
As of March 4, the Huo-Yan laboratories have completed a total of 360,000 test samples across China, enabling a rapid response to the outbreak including diagnosis of suspected cases, identification of suspected cases, release of recovered patients, and screening of close contacts and high-risk groups.
Huo-Yan Laboratory Package for Partners:
BGI has now made the Huo-Yan Laboratory into a comprehensive and easy-to-implement anti-epidemic pathogen detection solution available to customers worldwide. In addition to PCR systems and biosafety cabinets, the laboratory is typically equipped with automated nucleic acid extraction systems, thus greatly improving the efficiency.
The Huo-Yan laboratory solution package includes:
– Laboratory Design
– Equipment, Reagent, Consumables
– Assembly, Optimisation and Staff Training
– Technology Transfer
– Laboratory Operation Support
– Huo-Yan Laboratory Certification
BGI has developed an established process designed to ensure the efficient and economical set-up of your laboratory. Our dedicated and professional team will guide you through the entire process, from laboratory design to active service.
On January 14, BGI successfully developed a Real-Time Fluorescent RT-PCR kit for detecting 2019-nCoV (SARS-CoV-2), which can issue results in 3 hours. The kit was certified by National Medical Products Administration and received CE-IVD marking. The kit is already widely used in China, providing a scientific basis for diagnosis of suspected cases and the discharge of recovered patients.
As one of the world’s leading genomics companies, BGI already has a long and extensive experience in establishing laboratories across the world with local partners, gained from its provision of genetic testing services.
With 6000 employees and offices across the world, BGI is able to leverage its experience and network to offer effective and affordable omics solutions to partners worldwide.
Visit www.bgi.com for more information.
Contact us today to learn more about the Huo-Yan Laboratory Solution and how it can be established locally to help fight the spread of COVID-19 worldwide.